

1 **Type: Systematic Review**

2 **The Long and Winding Road: A Systematic Literature Review Conceptualising**  
3 **Pathways for Hypertension Care and Control in Low- And Middle-Income Countries**

4 **Abstract**

5 **Background:** Hypertension control is poor everywhere, especially in low- and middle-income  
6 countries (LMICs). An effective response requires understanding factors acting at each stage  
7 on the patients' pathway through the health system from entry or first contact with the health  
8 system, through to treatment initiation and follow up. This systematic review aimed to identify  
9 barriers to and facilitators of hypertension control along this pathway and, respectively, ways  
10 to overcome or strengthen them.

11  
12 **Methods:** MEDLINE, EMBASE, Global Health, CINAHL Plus, and Africa-Wide Information  
13 (1980-April 2019) were searched for studies of hypertensive adults in LMICs reporting details  
14 of at least two adequately described health system contacts. Data were extracted and analysed  
15 by two reviewers. Themes were developed using NVivo in patient-related (socio-demographic,  
16 knowledge and health beliefs, health status and co-morbidities, trade-offs), social (social  
17 relationships and traditions) and health system domains (resources and processes).  
18 PROSPERO reregistration: CRD42017074786. Results are reported according to PRISMA  
19 guidelines.

20  
21 **Results:** From 2,584 identified records, 30 were included in the narrative synthesis. At entry,  
22 'health systems resources and processes' and 'knowledge and beliefs about hypertension'  
23 dominated while 'social relations and traditions' and 'comorbidities' assume greater  
24 importance subsequently, with patients making 'trade-offs' with family priorities during follow  
25 up. Socio-demographic factors play a role, but to a lesser extent than other factors. Context  
26 matters.

27  
28 **Conclusion and implications:** Understanding the changing barriers to hypertension control  
29 along the patient journey is necessary to develop a comprehensive and efficient response to  
30 this persisting problem.

1 **Introduction**

2

3 **Background**

4 Hypertension is the leading preventable cause of illness and premature death worldwide <sup>1</sup>. It is  
5 easily diagnosed and can be controlled with relatively simple interventions. Yet it is often  
6 unrecognised. When diagnosed, it requires life-long management and patients may be unaware  
7 of the need for continuous monitoring and adherence to treatment, which can be difficult to  
8 achieve. Moreover, while diagnosis and initiation of medication usually takes place in primary  
9 care, its management involves all levels of the health system, with referral to specialists if  
10 certain complications arise. Interventions to improve care have achieved modest results, and  
11 control remains surprisingly poor in countries at of all income levels <sup>2</sup>. It is increasingly  
12 recognised that to be effective, responses must cover the entire patient pathway, from initial  
13 diagnosis through to long term treatment and, hopefully, control.


14

15 **Conceptualisation of Patient Pathway**

16 Clinical guidelines typically portray the patient pathway as a linear process from diagnosis and  
17 initiation of medication to follow-up. Yet many journeys are much more complex, especially  
18 as several attempts may be needed to achieve initial control, and as hypertension is increasingly  
19 only one of several conditions affecting the patient. Figure 1 presents some archetypal  
20 pathways applicable to hypertension, and non-communicable disease in general. Which one a  
21 given patient will follow depends not only on their clinical condition but also their socio-  
22 economic characteristics, preferences, health beliefs, and features of the health system.

23

24 *Figure 1 Conceptualisation of patient pathway for non-communicable disease*



1 Many existing guidelines divide the pathway into stages before and after initiation of treatment  
2 ('after' often being defined in diverse ways). They also assume, often implicitly, that once the  
3 patient is in the system, their growing familiarity with both it and their condition means that  
4 the barriers diminish. Few consider the barriers and enablers that act throughout their journey.  
5 Nor do they consider, in any detail, that the patient can interrupt, terminate or re-enter treatment  
6 at any point. Their decision to continue with treatment or not is shaped by a complex mix of  
7 knowledge, preferences, and judgements. Importantly, the factors triggering these decisions  
8 can accumulate, for example when patients face repeated long clinic waits or medicines  
9 shortages and in response seek alternative, less effective forms of care.  
10 This review seeks to synthesise the empirical evidence on what hampers or facilitates the  
11 patient at each stage along the pathway from entry to the health system to achieving  
12 hypertension control. This comprehensive approach fills a major gap in the literature.

13

14 **Methods**

15

16 The study protocol uses the Preferred Reporting Items for Systematic Reviews and Meta-  
17 Analyses (PRISMA) guidelines and was registered with the International Prospective Register  
18 of Systematic Reviews (PROSPERO: CRD42017074786)<sup>3</sup>.

19

20 **Research Questions**

- 21 1. How do patients with hypertension move through the health care system, over time and  
22 across different levels and types of care?
- 23 2. What are the barriers and enabling factors at each stage of the patient pathway? Which  
24 relate to the health system and which to patient characteristics and their families and social  
25 networks, and how?
- 26 3. How can the patient be helped to navigate the pathway successfully?

27

28 Initially, we also sought evidence on how different pathways relate to health outcomes but the  
29 necessary literature was lacking.

30

31 **Key Concepts and Assumptions**

32 A *Health system* comprises “all organizations, people, [resources] and actions whose primary  
33 intent is to promote, restore or maintain health [at the individual or population level]”<sup>4</sup> Both

1 supply-side factors (health systems structures and processes) and demand-side factors (patient  
2 choices) influence patient progression.

3

4 *Pathway* is understood as the patient's progression through the health system, with the intended  
5 destination being control of hypertension without side effects and avoidance of complications.

6

7 *Point of contact* is where the patient interacts with the health system or alternative providers.

8 We conceptualise the patient pathway as having three distinct stages, which we used to  
9 categorise the studies we included, while noting, as above, that the journey is often non-linear.

10 The first is the initial contact with the health system (entry), perhaps associated with symptoms  
11 that may or may not be related to the diagnosis, and any decision to seek care. This includes  
12 all studies that describe diagnosis (either in a facility or during a community-based screening  
13 programme). The second, treatment initiation, begins with the first prescription and ends with  
14 being established on treatment. For those identified during community screening events, this  
15 stage also includes the moment when they contacted the formal health system and were  
16 provided with care (medicine and advice about nutritional or life-style changes), and not simply  
17 when they were diagnosed. This stage may include a referral to another level of the health  
18 system. The third is long-term management, when the patient has become established on  
19 treatment and they should be receiving follow-up by a designated provider but also including  
20 further referral, and departure and re-entry into the system (for the existing or new condition).  
21 There was, however, a fourth set of studies that do not fall within these stages but instead  
22 discuss pathways overall or in general. The distinction between stages allows us to identify  
23 common pathways through the system but overlaps between stages were common.

24

## 25 **Inclusion and Exclusion Criteria**

26 The review included studies:

- 27 • of adults with hypertension (SBP>140 mmHg +/-or DBP>90 mmHg)
- 28 • from low- and middle-income countries (LMICs)
- 29 • including at least two reported contacts with the system or data gathered over a period  
30 when more than one contact with the health system was anticipated
- 31 • reporting empirical findings studies (qualitative or quantitative)
- 32 • of any design
- 33 • in English.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33

In addition, studies (mainly qualitative) were included if they elicited patient experiences that span the length of their journey, even if not fully distinguishing stages of treatment. These also included studies where patients followed unconventional routes, including self-treatment. It excluded studies:

- of subjects under 18 years, or not having hypertension
- of patients with pregnancy induced or secondary hypertension
- from high-income countries or conducted before 1980.
- including data on only one contact and no information on subsequent stages (studies that asked patients to recall previous treatment stages were also excluded)
- not distinguishing clearly between any stages of treatment.

### **Search Strategy**

The search was conducted by RB in 5 databases; MEDLINE, EMBASE, Global Health, CINAHL Plus, and Africa-Wide Information, for all relevant articles published after 1980 until 12 April 2019. A combination of key words, phrases, and medical subject headings (MeSH) for the main concepts; ‘low and middle income countries’, ‘hypertension’, ‘continuity of care’, and ‘epidemiological studies’ were used (see Annex for a full search strategy in MEDLINE).

### **Extraction and Critical Appraisal for Quality Assessment**

Two independent reviewers (RB, EH) reviewed all identified abstracts by title and abstract against the inclusion criteria. Full texts of those retained were then read by the reviewers. A third reviewer (DB) adjudicated disagreements on eligibility.

The extraction template contained fields for study objectives, how hypertension was defined, study design, sample size and socio-demographic description of study population, research methods, risk of bias, country and health care settings (including level of the health system), description of each contact along the patient pathway, and barriers and enablers at each stage, if available. It distinguished the different contacts along the pathway and, where this was not possible, information on barriers and facilitators related to more than one contact was included. We critically assessed the quality of included articles using standardised checklists for observational studies (STROBE), randomised controlled trials (CONSORT), and qualitative and mixed method research (SRQR) as appropriate<sup>5-7</sup>. Articles that met at least 80% of these standards were categorised as ‘high quality’, ‘moderate quality’ if they met between 60% and

1 80% of relevant standards, and ‘low quality’ if they met less than 60%. Of the 30 included  
2 studies, 9 were assessed as high quality, 18 as moderate, and 3 as low quality. Data were  
3 extracted by the two reviewers independently and any differences were resolved by discussion  
4 with the third reviewer.

5


6 **Analytical Strategy**

7 We used a mix of inductive and deductive analytical approaches. First, two reviewers  
8 independently thematically coded barriers and enablers of care for each of the stages described  
9 above in NVivo 11.0 (QSR International). Codes were then compared and discussed with the  
10 third reviewer and aggregated into non-exclusive categories (domains). This process of  
11 conceptualisation reflected both groupings of key themes within papers, but also codes on  
12 barriers and enablers identified from the broader literature from health systems, medical  
13 anthropology and sociology. This process was iterative; with coding followed by re-  
14 organisation of the codes, assessing their level of importance according to their prevalence and  
15 strength of evidence, followed by a further coding. This ensured that the overarching codes are  
16 distinct and represent a meaningful representation of the key barriers and enablers at different  
17 stages of hypertension care. The final typology consisted of the following six domains, also  
18 represented in Figure 2.

19

20

1 *Figure 2 Typology of main domains of barriers and enablers influencing patient*  
 2 *pathway*



3

4

5 *Demographics and socio-economic factors* included sex, age, and other individual  
 6 characteristics associated with access to and use of health services.

7

8 *Health systems resources and processes* included availability, accessibility and affordability of  
 9 resources, such as health workers, facilities, medicines, and models of care acceptable to  
 10 patients. These often assume different degrees of importance during each stage of the pathway  
 11 <sup>8</sup>.

12

13 *Patients' (and families) knowledge and beliefs of hypertension.* Studies of medical pluralism  
 14 and syncretism find that biomedical and local or folk knowledge and beliefs about illness often  
 15 interact, facilitating care or creating barriers to it and to adherence to medication <sup>9-11</sup>. These  
 16 often reflect how people think about their bodies over the life cycle <sup>12</sup>. This domain included  
 17 knowledge and beliefs about hypertension and bodies, how these may change over time, and  
 18 how these may impact on adherence to formally mandated pathways.

19 *Health status and co-morbidities* were particularly helpful in understanding ways in which  
 20 multiple co-morbidities complicate patient pathways. Given the largely asymptomatic nature  
 21 of hypertension, we also considered ways in which lack of symptoms impacted on seeking

1 treatment at all points of contact. Conversely, entering the health system in a quest for treatment  
2 of co-morbidities was sometimes a trigger to manage asymptomatic hypertension.

3

4 *Social relationships and traditions.* Drawing on medical anthropology<sup>13-16</sup> and research that  
5 recognises health systems as social institutions<sup>17,18</sup> we identified themes around social  
6 relationships (between the patient and their family, local community; and between the patient  
7 and health staff) impact on the patient pathway. Traditions (the association of particular foods  
8 with social events and stages in the life cycle) were coded under this domain.

9 *Trade-offs related to the pathways.* Seeking care in LMICs often comes at a cost, financial or  
10 otherwise, not only for the individual but their family. It often places significant burdens on  
11 family welfare. This domain was concerned with how these broader responsibilities influenced  
12 the pathway. While some studies saw this issue in terms of psychological factors (e.g.  
13 forgetfulness in those with competing duties), others viewed patients as making rational trade-  
14 offs as part of their coping strategy and balancing different life and treatment decisions.  
15 Complex trade-offs made during the treatment pathway are increasingly discussed<sup>8</sup>.

16

17 Given the nature of the data collected, the variation in terminology, definition of each stage a  
18 narrative synthesis was employed. Findings are structured under the three key treatment stages  
19 (entry, treatment, follow-up), and within each, grouped under the 6 domains.

20

## 21 **Results**

22

### 23 **Description of Included Studies**

24 The flow chart, from 1,945 abstracts identified by title and abstract to the 30 included in the  
25 final synthesis, is displayed in Figure 3.


26

27



1 *Figure 3 Literature flow-PRISMA Flow Chart*

2  
3



4  
5  
6  
7  
8  
9  
10  
11

1 **Description of Hypertensive Patients**

2 The studies included, and their main characteristics, are described in Table 1. Most studies  
3 were conducted in East and South-East Asia (China <sup>19-22</sup>, Vietnam <sup>23</sup>, Malaysia <sup>24</sup>, Indonesia  
4 <sup>25</sup>) or sub-Saharan Africa (Ethiopia <sup>26</sup>, Ghana <sup>27-29</sup>, Kenya <sup>30-32</sup>, Namibia <sup>33</sup>, Nigeria <sup>34</sup>, Tanzania  
5 <sup>35</sup>, and Uganda <sup>36</sup>); and Egypt <sup>37</sup>. 3 studies were in Central and South America (Belize <sup>38</sup>, Brazil  
6 <sup>39-41</sup>, Colombia <sup>42</sup>, Mexico <sup>43</sup>); 1 in South Asia (India <sup>44</sup>) and 1 in the Middle East (Iran <sup>45</sup>).

7

8 Eighteen studies were quantitative, 9 qualitative, and 3 used mixed methods. Among the  
9 quantitative studies, there were 8 prospective cohorts <sup>19-21,23,28,35,36,38</sup>, three cross-sectional  
10 studies <sup>24,37,39</sup>, and one prospective randomised control trial <sup>22</sup>. Studies using qualitative  
11 research methods employed a mixture of semi-structured and in-depth interviews, focus group  
12 discussions, and ethnographic investigations into patients' past experiences in seeking care for  
13 hypertension and or adherence to medication. In longitudinal studies, participants were  
14 followed up for periods from 26 days <sup>28</sup> to 17 months <sup>23</sup>.

15

1 Table 1 Barriers and facilitators of patient progression in the health systems

Stage	Domain	Themes	Author and Country
Entry & diagnosis	Health systems resources & processes	- Patients from mass screening do not return for confirmation or diagnosis, little routine monitoring	Risso Gill et al., 2015 (Malaysia), Shima et al., 2014 (Malaysia)
		+ Adequate health systems resources, mass screening, routine screening, work-place screening	Risso-Gill et al., 2015 (Malaysia), Nations et al., 2011 (Brazil), Legido-Quigley et al 2015 (Colombia), Youssef and Moubarak, 2002 (Egypt)
	Knowledge and beliefs about hypertension	- Limited information and poor understanding of causes, symptoms; feeling well	Legido Quigley et al., 2015 (Colombia), Naanyu et al 2016 (Kenya), Risso Gill et al 2015 (Malaysia), Gabert et al., 2017 (India)
		+ Having symptoms	Legido Quigley et al., 2015 (Colombia), Risso Gill et al., 2015 (Malaysia), Shima et al., 2014 (Malaysia)
Progressing through the system: initiation of treatment, first referral	Demographics and socio-economic factors	- Poverty, work responsibilities and need to balance care needs with other daily needs	Bovet et al., 2008 (Tanzania), Kotwani et al., 2014 (Uganda), Naanyu et al., 2016 (Kenya), Rachlis et al., 2016 (Kenya)
		+ More advanced age	Bovet, 2001 (Tanzania), Chung, 2005 (Belize), Kotwani et al., 2014 (Uganda), Nguyen et al., 2011 (Vietnam)
		+/- Being employed, higher education, being female	Chung et al., 2005 (Belize), Kotwani et al., 2014 (Uganda), Naanyu et al., 2016 (Kenya)

	Health status and co morbidity	- History of other chronic diseases, behavioural risk factors, milder hypertension, forgetfulness, poor motivation, lack of symptoms	Nguyen et al., 2011 (Vietnam), Rachlis et al., 2016 (Kenya), Bovet et al., 2008 (Tanzania), Kotwani et al (Uganda), Naanyu et al, 2016 (Kenya), Rachlis et al 2016 (Kenya), Rahmawati & Bajorek, 2015 (Indonesia)
		+ Severe hypertension, current tobacco use, higher initial blood pressure, personal history of hypertension or CVD, worsening health status, being overweight, personal initiative	Bovet et al., 2008 (Tanzania), Chung et al., 2005 (Belize), Nguyen et al., 2011 (Vietnam), Rachlis et al., 2016 (Kenya), Kotwani et al (Uganda)
		+/- Alcohol use, family history of CVD or hypertension, worsening health status/ severe hypertension	Naanyu et al., 2016 (Kenya), Rachlis et al., 2016 (Kenya), Kotwani et al., 2014 (Uganda), Nguyen et al., 2011 (Vietnam)
	Health systems resources and processes	- Costs associated with care and treatment, treatment and traditional remedies available outside health system, poor quality of care, lack of staff and/or specialised treatment, long queues, longer distance and higher cost of transport, poor linkage following community level entry	Bovet et al., 2008 (Tanzania), Kotwani et al., 2014 (Uganda), Naanyu et al., 2016 (Kenya), Nguyen et al., 2011 (Vietnam), Rachlis et al., 2016 (Kenya), Rahmawati & Bajorek, 2015 (Indonesia), Risso Gill et al., 2015 (Malaysia), Shima et al., 2014 (Malaysia), Subramanian et al. 2018 (Kenya)
		+ Availability and training of healthcare providers, accessible of clinic, Comprehensive counselling and appropriate referral	Nguyen et al., 2011 (Vietnam), Rachlis et al., 2016 (Kenya), Kotwani et al., 2014 (Uganda)

		+/- Availability of traditional remedies outside the health system	Naanyu et al., 2016 (Kenya), Rachlis et al., 2016 (Kenya), Bovet et al., 2008 (Tanzania)
	Knowledge and beliefs about hypertension	- Lack of knowledge and poor understanding about hypertension (especially symptomlessness), stigma	Bovet et al., 2008 (Tanzania) Chung et al., 2005, (Belize) Kotwani et al., 2014, (Uganda), Naanyu et al., 2016, (Kenya) Rahmawati and Bajorek, 2015, (Indonesia), Rachlis et al., 2016 (Kenya), Chung et al., 2015 (Belize)
		+ History of hypertension, community awareness, sensitisation/ education	Chung et al., 2015 (Belize), Rachlis et al., 2016 (Kenya)
	Social relations and traditions	- Family responsibilities, fear of being screened for stigmatised disease (HIV), lack of social or family support, poor relationships between patient and health worker	Kotwani et al., 2014 (Uganda), Naanyu et al., 2016 (Kenya), Rachlis et al., 2016 (Kenya)
+ Good provider patient relationships, concerns about family responsibilities, peer, family and social support		Rachlis et al., 2016 (Kenya)	
	Trade-offs	- Balancing care needs with other daily demands including work and home	Rachlis et al., 2016 (Kenya), Naanyu et al., 2016 (Kenya), Kotwani et al., 2014 (Uganda)
Follow up stage/ retention in the system	Demographics and socio-economic factors	+ / - Older age, higher education, gender, lower socio-economic status	Harries, 2005 (Ghana), Legido Quigley et al., 2015 (Colombia), Nashilongo et al., 2017 (Namibia), Nations et al., 2011 (Brazil), Rachlis et al., 2016 (Kenya), Ramli et al., 2012 (Malaysia), Sarfo et al., 2018 (Ghana),

			Youssef & Moubarak, 2002 (Egypt), Wong et al., 2009 (Hong Kong), Wong et al., 2011 (Hong Kong), Wong et al. 2015 (Hong Kong)
	Health status and co-morbidity	+/- Comorbidities, Higher blood pressure, severity of hypertension	Atinga et al., 2018 (Ghana), Harries et al., 2005 (Ghana), Legido Quigley et al., 2015 (Colombia), Mekonnen et al., 2017 (Ethiopia), Nashilongo et al., 2017 (Namibia), Nations et al., 2011 (Brazil), Nayeri et al., 2015 (Iran), Nguyen et al., 2011 (Vietnam), Ramli et al., 2012 (Malaysia), Wong et al., 2009 (Hong Kong), Wong et al., 2011 (Hong Kong)
		- Lack of symptoms	Nations et al., 2011 (Brazil), Nayeri et al., 2015 (Iran), Odusola et al., 2014 (Nigeria), Rahmawati & Bajorek, 2015 (Indonesia), Youssef and Moubarak, 2002 (Egypt) Zhao et al., 2012 (China)
		+ Feeling ill or improving under exercise program	Nayeri et al., 2015 (Iran), Rahmawati & Bajorek, 2015 (Indonesia)

	Health systems resources & processes	+/- Costs associated with receiving care and medicine	Emmerick et al., 2017 (Brazil), Legido Quigley et al., 2015 (Colombia), Mekonnen et al., 2017 (Ethiopia), Nations et al., 2011 (Brazil), Odusola et al., 2014 (Nigeria), Rachlis et al., 2016 (Kenya), Rahmawati & Bajorek, 2015 (Indonesia), Wong et al., 2009 (Hong Kong), Wong et al., 2015 (Hong Kong), Sarfo et al., 2018 (Ghana)
		- Complex medication regimes, polypharmacy, side effects, use of traditional medicine	Atinga et al., 2018 (Ghana), Harries et al., 2005 (Ghana), Legido Quigley et al., 2015 (Colombia), Nations et al., 2011 (Brazil), Nayeri et al., 2015 (Iran), Odusola et al., 2014 (Nigeria), Rachlis et al., 2016 (Kenya), Ramli et al., 2012 (Malaysia), Risso-Gill et al., 2015 (Malaysia), Sarfo et al., 2018 (Ghana), Shima et al., 2014 (Malaysia), Youssef & Moubarak, 2002 (Egypt), Wong et al 2009 (Hong Kong), Wong et al 2015 (Hong Kong), Zhao et al., 2012 (China)
		- Poor quality of service (lack of follow-up, tracing of patients, reminders of appointments, lack of explanation of treatment, short, infrequent visits, slow service and lack of appointments, visiting multiple clinics, lack of	Atinga et al 2018 (Ghana), Gabert et al., 2017 (India), Legido Quigley et al., 2015 (Colombia), Nashilongo et al., 2017 (Namibia), Nations et al., 2011 (Brazil), Nayeri et al., 2015 (Iran), Odusola et al., 2014 (Nigeria), Rachlis et al., 2016 (Kenya), Rahmawati & Bajorek, 2015

		specialist services – especially related to patients being seen by general practitioners or in accident and emergency settings, lack of medicine), distance to the health centre or pharmacy.	(Indonesia), Risso Gill et al., 2015 (Malaysia), Sarfo et al., 2018 (Ghana), Shima et al., 2014 (Malaysia), Wong et al., 2009 (Hong Kong), Wong et al., 2015 (Hong Kong), Zhao et al 2012 (China)
		+ Pharmacist involvement or private sector providers, good relationships between providers and patients	Atinga et al., 2018 (Ghana), Gabert et al., 2017 (India), Mekonnen et al., 2017 (Ethiopia), Risso Gill et al., 2015 (Malaysia), Wong et al., 2015 (Hong Kong), Zhao et al., 2012 (China)
	Knowledge and beliefs about hypertension	+ Good knowledge about hypertension or appropriate food to eat and weight loss, favourable attitude, faith in treatment or orthodox/ biomedicine medicines	Legido Quigley et al., 2015 (Colombia), Mekonnen et al., 2017 (Ethiopia), Nayeri et al., 2015 (Iran), Odusola et al., 2014 (Nigeria), Rachlis et al., 2016 (Kenya), Ramli et al., 2012 (Malaysia), Youssef & Moubarak, 2002 (Egypt)
		- Poor knowledge about hypertension, Belief that the body can recover by itself, that medication brings cure, that high blood pressure is part of being old or is transient, that medicines damage the body. Belief in witchcraft and spells	Atinga et al., 2018 (Ghana), Legido Quigley et al., 2015 (Colombia), Manto et al 2018, Nayeri et al., 2015 (Iran), Odusola et al., 2014 (Nigeria), Rachlis et al., 2016 (Kenya), Risso Gill et al., 2015 (Malaysia), Shima et al., 2014 (Malaysia), Zhao et al., 2012 (China), Manto et al 2018 (Cameroon)



		+ pressure of employers to be healthy, personal initiative, desire to be healthy	Legido Quigley et al., 2015 (Colombia), Rachlis et al., 2016 (Kenya), Rahmawati & Bajorek, 2015 (Indonesia), Risso Gill et al., 2015 (Malaysia)
	Trade offs	- Pressures of paid work, domestic work, unwillingness to defer gratification, low motivation or will power	Nayeri et al. 2015 (Iran), Nashilongo et al., 2017 (Namibia), Atinga et al., 2018 (Ghana), Legido-Quigley et al., 2015 (Colombia) Rachlis et al., 2016 (Kenya), Rahmawati and Bajorek, 2015 (Indonesia)
		+ Employer pressures on employee to be healthy, personal desire to be health	Rahmawati and Bajorek, 2015 (Indonesia), Risso-Gill et al. 2015 (Malaysia)
	Social relations and traditions	- Lack of social support, misinformation from community peers and the media, poor relationships and communication between patients and health staff,	Legido Quigley et al., 2015 (Colombia), Nations et al., 2011 (Brazil), Nayeri et al., 2015 (Iran), Odusola et al., 2014 (Nigeria), Rachlis et al., 2016 (Kenya), Risso Gill et al., 2015 (Malaysia), Rahmawati and Bajorek 2015 (Indonesia), Shima et al., 2014 (Malaysia)
		+ Supportive relatives and communities, good relationships between patients and staff, good social reputation of doctor	Legido- Quigley et al 2015 (Colombia) Nashilongo et al., 2017 (Namibia), Nayeri et al., 2015 (Iran), Odusola et al., 2014 (Nigeria), Rachlis et al., 2016 (Kenya), Rahmawati & Bajorek, 2015 (Indonesia), Shima et al., 2014 (Malaysia)

		+/- Local cultural practices and traditions	Atinga et al., 2018 (Ghana), Legido Quigley et al., 2015 (Colombia), Nayeri et al., 2015 (Iran), Nations et al 2011., (Brazil), Odusola et al., 2014 (Nigeria), Rachlis et al., 2016 (Kenya), Risso Gill et al., 2015 (Malaysia), Youssef & Moubarak, 2002 (Egypt)
Barriers and facilitators not specific to a single stage	Demographics and socio-economic factors	+ Older age, being female	Ferreira et al., 2015 (Brazil)
		- Poor financial resources	Vedanthan et al., 2016 (Kenya)
	Health status and co-morbidity	+ being in poor health, being in good health, having co-morbidities (cancer, heart disease, diabetes)	Ferreira et al., 2015 (Brazil)
		- Costs of medication, consultation, lab tests, transport, difficulty of reaching facility, fear of stigma when care is provided by HIV clinic, poor timekeeping among staff, stock outs of medicines, dislike of nurse led services	Vedanthan et al., 2016 (Kenya)
	Health systems resources & processes	+ Being covered by health insurance, liking nurse led services	Ferreira et al., 2015 (Brazil), Vedanthan et al., 2016 (Kenya)
		- No symptoms, belief that symptoms relate to witchcraft not hypertension, lack of knowledge and community awareness of hypertension	Vedanthan et al., 2016 (Kenya)

	Knowledge and beliefs about hypertension	+ Fear of mortality	Vedanthan et al., 2016 (Kenya)
		- Lack of patient satisfaction	Vedanthan et al., 2016 (Kenya)
	Social relations and traditions	+ Strong community support, patient satisfaction and trust between patients and nurses	Vedanthan et al., 2016 (Kenya)

1

1 **Stage 1: Entry to the health system**

2 Most studies examined patients recruited after initial diagnosis in primary care<sup>28,37,38,40,42,46,47</sup>,  
3 followed by community screening programmes<sup>23,35,36</sup>. Only five described facilitators and  
4 impediments to initiation of contact by patients with the health system<sup>37,40,42,46,47</sup>. These fell  
5 into two domains: health systems, and knowledge and beliefs.

6  
7 *Health systems resources and processes*

8 The most consistent facilitator of diagnosis was the practice of checking blood pressure during  
9 attendance at primary care, which took on particular significance given that hypertension is  
10 largely symptomless until severe, and with any symptoms that are present often non-specific.  
11<sup>37,42,46,47</sup>. The widespread failure to do this was linked to the high proportion of patients  
12 diagnosed at an advanced stage with symptoms, 60% of the patients in one Egyptian study<sup>37</sup>.  
13 Similar findings were reported from Malaysia<sup>46,47</sup> and Brazil<sup>40</sup>. Many countries organise mass  
14 screening events but, as Risso-Gill and colleagues note in Malaysia, few patients subsequently  
15 attend to have their diagnosis confirmed<sup>46</sup>.

16  
17 *Knowledge and beliefs*

18 Five studies described how the combination of lack of symptoms and low awareness of its  
19 asymptomatic nature impacts on treatment seeking at the time of initial diagnosis<sup>42,44,46-48</sup>. Poor  
20 understanding of the importance of treating hypertension<sup>42,47</sup> also act as barriers.

21  
22 **Stage 2: Initiation of Treatment**

23 The second stage is when patients have received a diagnosis and been advised to seek care or  
24 have been formally referred into the system from community screening events. Studies  
25 followed patients for 17 months<sup>23</sup> 12 months<sup>35</sup>, six months<sup>36</sup>, and four months<sup>38</sup> while  
26 qualitative studies interviewed patients about their overall experience but did not always  
27 specify which stage of the pathway was involved<sup>25,30,46</sup>. Two reported interventions with  
28 components to improve linkage with the health system following screening<sup>35,36</sup>. Linkage is a  
29 term originally used in screening for HIV, referring to establishing a link between the patient  
30 and health care. In Tanzania, patients were provided with information about hypertension<sup>35</sup>  
31 but it had little impact on health seeking behaviour. In Uganda patients were provided with  
32 information, a voucher to cover transport costs, and a scheduled appointment<sup>36</sup>, which was  
33 much more successful. In this stage, barriers and enablers related to demographics, health

1 status, and poorly functioning health systems were most important, although differently in each  
2 context.

3

#### 4 *Demographics and socio-economic factors*

5 Four studies reported that older age correlated with greater propensity to seek care after  
6 diagnosis, within a community based programme<sup>23</sup>, the public sector<sup>36,38</sup> and in a mix of public  
7 and private systems<sup>35</sup>.

8

9 Researchers explored concerns about how costs of treatment affected linking and initial  
10 attendance (see below). The negative impact of financial constraints was described in two  
11 qualitative studies in eastern Kenya<sup>30,48</sup>, where they discouraged people from initiating care in  
12 the public sector, with a religious leader noting that "...when somebody is poor it becomes a  
13 silent killer...".

14

15 In Belize, Uganda, and Vietnam, being female was associated with an increased likelihood of  
16 seeking care after detection during screening events.<sup>23,36,38</sup> However, a qualitative study in  
17 Kenya identified women's lack of control over financial decision making as a barrier to  
18 accessing care<sup>30</sup>. This study also reported men being less likely to seek care unless  
19 experiencing severe symptoms.

20

21 Higher educational and occupational status also facilitated seeking care<sup>36</sup> while in rural  
22 Uganda patients employed in manual labour (e.g. farming) were more likely to link than those  
23 who were unemployed<sup>36</sup>.

24

#### 25 *Health status and co-morbidities*

26 This domain highlighted the importance of co-morbidities and a family history of coronary  
27 disease. In Vietnam<sup>23</sup> and Kenya<sup>30</sup> behavioural risk factors for cardiovascular disease (CVD)  
28 reduced the probability of seeking care, but in Uganda, alcohol and tobacco use and were  
29 associated with increased likelihood of progressing through the health system<sup>36</sup> and in  
30 Tanzania overweight patients were also more likely to seek care, although the association was  
31 only just significant<sup>35</sup>. Having a family history of hypertension was a predictor of linkage to  
32 care in Uganda<sup>36</sup>, but not in Vietnam<sup>23</sup>. In both Vietnam and Belize, those with a personal  
33 (rather than family) history of CVD were more likely to join a hypertension programme<sup>23,38</sup>.

1 Milder hypertension independently predicted not seeking care in a community programme in  
2 Vietnam following diagnosis as did a history of other chronic diseases (explained by these  
3 patients seeking treatment elsewhere)<sup>23</sup>. Finally, worsening health status was considered a  
4 barrier to seeking care in Kenya<sup>30</sup>, while severe hypertension facilitated joining a programme  
5 in Vietnam<sup>23</sup>.

6  
7 The lack of symptoms associated with hypertension was identified as a barrier to seeking care  
8 following diagnosis in five studies<sup>25,30,35,36,48</sup>. Naanyu proposed that gender played a role, as  
9 men are reluctant to go to a health centre unless they have a debilitating illness. One qualitative  
10 study identified forgetfulness and poor motivation as psychological barriers and personal  
11 initiative as a facilitator to linkage<sup>30</sup>.

### 13 *Health system resources and processes*

14 Inadequacies in the health system were identified as barriers to seeking care at health facilities.  
15 Kenyan clinics lacked staff, equipment, and medication<sup>30</sup>. In Malaysia, patients referred for  
16 advice on lifestyle changes were unable to see a dietitian<sup>47</sup>. Naanyu and Rachlis both described  
17 how unavailability of medicines in pharmacies and availability of herbal medicine from  
18 traditional healers diverted patients from the Kenyan public health system<sup>30,48</sup>. However, in  
19 Tanzania Bovet and colleagues found this to be a very minor problem, as only one of 161  
20 patients sought care from a traditional practitioner<sup>35</sup>. However, they did find cost to be a barrier  
21 to continued attendance. In Kenya, costs of diagnosis and treatment, even in relation to public  
22 or subsidised services, pose a significant burden, and may lead to catastrophic expenditure<sup>32</sup>.

23  
24 In Kenya, the expectation of long queues and poor-quality services was a barrier to linkage<sup>48</sup>.  
25 Kenyan patients also feared being screened for HIV at facilities and avoided them.

26  
27 Distance to a health facility influenced whether patients referred after screening would attend  
28 in rural Uganda<sup>36</sup>, Kenya<sup>30</sup>, Vietnam<sup>23</sup> and Indonesia<sup>25</sup>. This was borne out in qualitative  
29 studies<sup>30,25</sup>. In Malaysia, Rahmawati reflects on the difficulties that some elderly patients  
30 might have in getting to mobile clinics. Yet proximity to health services did not always  
31 improve uptake, Bovet et al report that in Dar Es Salaam, where services are near patients,  
32 uptake of appointments and treatment was very low<sup>35</sup>.

1 *Knowledge and beliefs*

2 Studies in Kenya and Belize identified poor understanding of hypertension among those not  
3 seeking care after its detection<sup>30,38</sup> coupled with doubt that medicine could alleviate symptoms,  
4 fear of taking it, and belief in witchcraft<sup>30</sup>. Several other studies suggest that the lack of  
5 knowledge that hypertension is often symptomless impacts on uptake of services<sup>25,35,36,38,48</sup>.  
6 The positive impact of education and awareness raising was described in two studies<sup>30,38</sup>,  
7 although this did not reach statistical significance in the study from Belize<sup>38</sup>.

8

9 *Trade-offs*

10 Competing family and work responsibilities prevented linkage to care in rural Uganda<sup>36</sup>,  
11 although transportation costs and difficulties were more frequently implicated. Obligations at  
12 work and home being prioritised against adhering to care were also cited qualitative research  
13 from Kenya, especially if services were of poor quality<sup>30</sup>. Naanyu also describes concerns  
14 about being a drain on their own and their families' resources<sup>48</sup>.

15

16 *Social relations and traditions*

17 Kotwani and Naanyu described how poor relations between health workers and patients in  
18 Uganda and Kenya were a barrier to seeking care following diagnosis<sup>36,48</sup>. In Uganda, fear of  
19 being reprimanded for missing a scheduled appointment was cited by 26% of the 27 people  
20 interviewed who had failed to take up referral following community screening<sup>36</sup>. Naanyu's  
21 study implicated fear of harsh language by health workers<sup>30</sup>. Rachlis described how good  
22 provider-patient relations were commonly reported to facilitate access to care following  
23 diagnosis<sup>30</sup>. Rachlis also identified lack of partner support and inadequate social support as a  
24 barrier<sup>30</sup>.

25

26 **Stage 3: Long term management**

27 This stage covers patients who, having been diagnosed, are successfully referred into the  
28 system, received medication or a prescription, or were being followed up (or 'linked'). Most  
29 studies of this stage of treatment addressed retention within the health system and adherence  
30 to medication (20 of 30)<sup>19-30,33,34,37,40-42,45-47</sup>. Barriers and facilitators were identified in all  
31 domains. That relating to health system resources was especially rich, with 21 studies reporting  
32 barriers related to financial, service delivery, medication, and geographical issues.

1 *Demographics and socio-economic factors*

2 The evidence is extremely mixed. Four studies, from China and Malaysia, found that adherence  
3 was better among older patients<sup>19-21,24</sup>, and women, who were also more likely to attend  
4 appointments<sup>19-21,24,30,40</sup>. A qualitative study from Brazil attributed lower adherence and  
5 attendances by men to a macho culture<sup>40</sup>, although another from Kenya reported how poor  
6 women had to prioritise domestic commitments and other calls on their finances<sup>30</sup>. The  
7 association with education varied<sup>28,37</sup>. The Brazilian study identified financial hardship as a  
8 barrier, with poorer patients less likely to seek continuing care after diagnosis or to use cheap  
9 proprietary remedies<sup>40</sup>. In Malaysia, as before, ethnic differences were reported, with those of  
10 Malay or Chinese origin more likely to adhere to medication than those of Indian origin, (1.68  
11 (95% CI: 1.03–2.73) and 2.64 (95% CI: 1.54–4.58 times, respectively)<sup>24</sup>. However, studies  
12 from Ghana and Namibia, found no significant association between age, sex, income,  
13 education/literacy, employment status, and adherence and hypertension control<sup>29,33</sup>.

14  
15 *Health status and co-morbidities*

16 The relationship between poor health, or presence of co-morbidities, and effective follow up is  
17 inconclusive. Four reported that patients with fewer or no co-morbidities were less adherent to  
18 treatment and antihypertensive medications<sup>19,20,26,28</sup>. In Malaysia, patients who also had  
19 diabetes were less likely to be adherent and have higher blood pressure who did not (OR: 1.74  
20 (1.289- 2.39)<sup>24</sup> and a qualitative study in Colombia reported that some patients with multiple  
21 conditions considered hypertension to be unimportant<sup>42</sup>. A qualitative study found that patients  
22 on multiple drug therapies stopped medication if they experienced adverse reactions and as  
23 advised by social networks<sup>27</sup>. In Vietnam, the dropout rate was significantly higher among  
24 those with mild than severe hypertension (21.5% and 8.2% respectively,  $p < 0.01$ )<sup>23</sup>. Some  
25 personality types (stressed, strict, irritable, depressive or obsessive) were linked to poor  
26 adherence, including to dietary restrictions, in Iran<sup>45</sup>, while a Brazilian study implicated  
27 depression, especially among those who lacked social support and where the service quality  
28 was poor<sup>40</sup>. However, a study from Namibia found that patients with HIV/AIDs did not have  
29 lower adherence<sup>33</sup>.

30  
31 The asymptomatic nature of hypertension was frequently invoked as an explanation for non-  
32 adherence<sup>22,25,34,37,40,45</sup>. For example, a Chinese study reported how those with uncomplicated  
33 hypertension simply do not feel “sick”<sup>22</sup> while, in Brazil, patients take medication according



1 to how they feel , taking half doses or skipping doses <sup>40</sup>. In Iran it was reported that some  
2 symptoms that patients associate with high blood pressure, such as numbness and blurred  
3 vision, increase adherence <sup>45</sup>. Finally, Rahmawati describes lack of transport for elderly  
4 patients to mobile clinics as a barrier, although the authors consider that it was not possible to  
5 distinguish whether failure to attend the mobile clinic was due to lack of transport or the  
6 asymptomatic nature of the disease <sup>25</sup>.

7

### 8 *Health system resources and processes*

9 Health systems barriers and facilitators to adherence and continuity of care could be found in  
10 all fifteen studies. As this was the richest domain, we sub-divided these factors into those  
11 related to financial, staffing and service delivery, medication, and geographic proximity.

12

13 *Financial:* Seven studies addressed this factor. In Colombia, barriers were created by gaps in  
14 coverage by the social security system and associated need for payment to doctors <sup>42</sup>, while  
15 studies in China and Nigeria link care free at the point of use with better adherence <sup>19,34</sup>. Two  
16 noted how those living in rural areas of Brazil and Colombia suffered a double disadvantage,  
17 as they were less likely to be covered by social security and the costs of medicines were higher  
18 <sup>40,42</sup>. A study of the Brazil's Farmácia Popular (FP) programme found major increases in  
19 continuity of treatment and adherence to medicines for NCDs when key essential medicines  
20 were provided for free, including through private sector pharmacies, while cost sharing by  
21 patients led to decreases <sup>41</sup>. In Ethiopia, adherence to medications was 2 times (AOR = 2.06,  
22 95% CI =1.13, 3.76) higher in respondents who obtain it at low or no cost compared to the rest  
23 <sup>26</sup>. In Indonesia, free blood pressure checks were considered to facilitate access to care <sup>25</sup>.  
24 However, Chinese studies reached different conclusions, with one finding greater adherence  
25 among those receiving public assistance <sup>21</sup> while another found it to be greater among those  
26 paying fees <sup>19</sup>.

27

28 In Ghana, in a study where study participants were covered by the insurance scheme and had  
29 guaranteed access to antihypertensive medications from hospital pharmacies, 20% reported  
30 problems in obtaining them and this was a significant predictor of poor hypertension control  
31 (OR 1.24 (1.02±1.49)<sup>29</sup>. Costs associated with purchasing medication was also cited as a barrier  
32 to care in Kenya <sup>30</sup>.

1 *Service delivery:* Six studies identified factors related to service delivery <sup>22,25,40,42,44-47</sup>. The  
2 most consistent finding was that retention of patients and adherence to treatment were better  
3 where health facilities were accessible, with short waiting times, longer duration of  
4 appointments with physicians, and offering care that is perceived to be of higher quality. A  
5 study from Namibia noted that many people were aware when their next appointment is but  
6 not attending it, suggest a lack of ways to track the patients or send reminders, as well as  
7 providing incentives <sup>33</sup>. One Chinese study found that an enhanced role for pharmacists  
8 (advising physicians of potential changes in medication and advising patients on adherence and  
9 life style), led to improved adherence <sup>22</sup>. Conversely, the perceived lack of physicians, nurses,  
10 supplies and diagnostic equipment, high patient volumes and public providers lacking time to  
11 counsel on mediations and adapting lifestyles, transportation and cost were common barriers  
12 to routine check-ups in primary care facilities, with quality sometimes better than in the private  
13 sector <sup>44</sup>. An absence of guidelines for BP measurement is also a supply-side barrier, as are  
14 stock-outs of drugs in public facilities, with patients needing to seek their medication in private  
15 pharmacies, thus incurring costs for travel and medication <sup>44</sup>. Long waiting times were  
16 identified as a barrier in seven studies <sup>29,30,34,40,42,44-46</sup>.

17 Counterintuitively, in Ghana, blood pressure control was poorer among those treated at a  
18 tertiary facility in dedicated hypertension clinics, mainly in urban areas (2.47 (1.57±3.87) than  
19 in rural primary healthcare facilities which despite these facilities more accessible; this may be  
20 due to poorer conditions and longer waiting times <sup>29</sup>. Longer duration of hypertension diagnosis  
21 also reduced the likelihood of successful control. A complex primary care intervention in  
22 Mexico involving a new cadre of community health workers, supply chain improvements,  
23 active case-finding, and education support for rural doctors did not lead to any significant  
24 improvement in blood pressure control among the population of Chiapas State <sup>43</sup>.

25  
26 *Medication-specific issues:* In addition to problems associated with purchasing medication (see  
27 above), four studies reported on availability (or lack thereof) of medicine <sup>30,34,42,45</sup>.  
28 Unsurprisingly, all reported lack of access, at health facilities <sup>42</sup>, in pharmacies <sup>34</sup>, and more  
29 generally <sup>45</sup> as a barrier to adherence.

30  
31 Twelve studies associated more complex medication regimes, polypharmacy with lower  
32 adherence <sup>19,21,22,24,28,29,34,40,42,45-47</sup>, while six noted the adverse impact of side effects of  
33 medication on adherence <sup>30,34,37,40,45-47</sup>, with one study from Malaysia finding that few patients  
34 were warned about them <sup>47</sup>. Specifically, unclear or ambiguous explanation of regimens or

1 polypharmacy by providers led to patients stopping or increasing medications (when feeling  
2 better or if concerned about side effects), researching and buying non-prescribed drugs<sup>27</sup>. In  
3 some studies the use of traditional medicine was associated with poor adherence<sup>28,45-47</sup> or  
4 described as an alternative to pharmaceuticals that were expensive or hard to find<sup>42</sup>.

5  
6 *Geographical accessibility:* Five studies<sup>19,30,34,42,46</sup> examined the role of proximity to health  
7 facilities. Four reported that patients living far away were less likely to attend but all were  
8 based on qualitative data<sup>30,34,42,46</sup>. Other studies found that greater distance from a clinic<sup>34</sup> or  
9 living in a different district than the hospital reduced adherence to medication<sup>19</sup>. Support for  
10 costs of transport from family members was reported to facilitate continuity of care in  
11 Colombia<sup>42</sup>.

### 12 13 *Knowledge and beliefs*

14 Fourteen studies identified limited knowledge about hypertension and its management as a  
15 barrier to adherence and retention<sup>22,24,26,27,30,33,34,37,40,42,45-47,49</sup>, while one study found that  
16 although literacy about antihypertensive medication (as distinct from consequences of  
17 hypertension) was high (83% of patients), there was no significant association with adherence  
18 and attending appointments<sup>33</sup>.

19  
20 Several themes emerged. One was that hypertension was viewed as a transient problem<sup>30,34,45</sup>.  
21 Some Malaysian patients described not taking medication as prescribed because of a belief in  
22 their ability to control their blood pressure with physical activity, diet, and stress management  
23<sup>47</sup>. A Chinese study found patients who believed they had been cured<sup>22</sup>. In Iran, while some  
24 believed that the body could recover by itself, others believed it was inherited and could not be  
25 treated<sup>45</sup>. In Ethiopia, users with a favourable attitude—a possible proxy for trust—about  
26 antihypertensive treatment were ten times (AOR = 9.88, 95% CI =5.34, 18.27) more likely to  
27 be adherent than others<sup>26</sup>.

28  
29 Another strand reflected broader perceptions of illness and disease. In several countries there  
30 was a belief that long term medication would cause damage to the body, especially the kidneys  
31<sup>49</sup>, or side effects<sup>27</sup> while in Egypt<sup>37</sup>, adherence was lower in those who believed that they  
32 were generally more likely than others to suffer misfortunes. In Ghana, perceptions that  
33 mainstream drugs were ineffective were associated with interrupting or terminating their

1 treatment and substituting herbal medicines and alternative therapies, including spiritual  
2 healing, prayers, and fasting, seen as protective from witchcraft and spells. The impact of these  
3 beliefs was accentuated by the greater ease of obtaining affordable alternative therapies as well  
4 as trusted relationships with native providers and a general belief that ‘medication is  
5 unnecessary because ill-health is an act of God’<sup>27</sup>. In Colombia and Brazil medication provided  
6 free of charge was sometimes considered inferior to that paid for. However, in Nigeria, faith in  
7 “orthodox medicines” (provided through the health system) was considered to improve  
8 adherence <sup>34</sup>.

9

10 One Malaysian study found a small, but statistically significant increase in adherence among  
11 patients with better knowledge of their medication (OR 1.03 – 1.01-1.04, p= 0.001)<sup>24</sup>, with  
12 similar findings from Egypt <sup>37</sup>. However, health workers often lacked educational material and  
13 provided little information to patients <sup>30,46</sup>. In Iran, patients identified information in the mass  
14 media as a source of information, although with mixed impact on adherence.

15

#### 16 *Trade-offs*

17 Eleven studies addressed trade-offs <sup>25,28,30,34,40,42,45-47</sup>. In Iran, patients reported how being busy  
18 working (either outside the home or undertaking childcare) increased the likelihood of  
19 forgetting to take medication <sup>45</sup>. However, in Malaysia, pressure from employers to be healthy,  
20 coupled with access to private providers facilitated adherence <sup>46</sup>. In Namibia, missing  
21 appointments was very common (75% ever missing a scheduled clinic appointment) and in  
22 60% of cases this was attributed to work commitments, despite being aware of the need for  
23 treatment <sup>33</sup>, while in Ghana ‘preoccupation with routine work’ and sustaining livelihoods,  
24 including having to travel away from home, led to de-prioritisation of medication (often framed  
25 as ‘forgetfulness’) <sup>27</sup>.

26

27 Seven studies addressed psychological factors <sup>25,28,30,40,42,45,47</sup>. An unwillingness to defer  
28 gratification was identified as a barrier to adherence to treatment, including diet in Iran <sup>45</sup>.  
29 Three studies identified low motivation or will-power as a barrier to retention <sup>25,30,42</sup> and in  
30 Indonesia the desire to be healthy was associated with enhanced continuity of care <sup>25</sup>.

#### 31 *Social relationships and traditions*

32 Eleven studies addressed these issues <sup>25,30,33,34,37,40,42,45-47</sup>. Relationships with families and  
33 friends could be either a facilitator or barrier to retention, with poor relationships with family

1 members impacting negatively on adherence<sup>30,34,47</sup>; lifestyle modification<sup>46</sup> and retention<sup>30,42</sup>  
2 while in several studies family support encouraged adherence<sup>30,34,45,47</sup> and retention in the  
3 system<sup>30,42</sup>. For example, support from friends and/or relatives were found to be critical for  
4 adherence through encouragement to take medication and attend follow-up appointments in  
5 Namibia<sup>33</sup>. There was little information on the role of local communities, although Shima  
6 reported how Indian patients in Malaysia were influenced by neighbours and friends when  
7 making decisions about adherence<sup>47</sup> while, in Indonesia, peer support was an important  
8 motivator for patients to participate in a community based programme for elderly patients<sup>25</sup>.

9  
10 Seven studies addressed local cultural practices and traditions<sup>27,30,34,37,42,45,46</sup>. Traditional  
11 practices could be a barrier to adherence<sup>34,46</sup> and continuity of care<sup>46</sup>. Thus in Ghana, there  
12 could be pressure on from peers, family, and relatives to choose traditional and herbal  
13 medicines, which were perceived to be safer, more effective and cheaper<sup>27</sup>. The presence of  
14 fatty food at social events also made lifestyle changes difficult<sup>40,42,45</sup>. In Nigeria, attitudes  
15 favouring smaller body size were linked to better adherence while in both Nigeria and Iran,  
16 those with stronger religious beliefs were more likely to be adherent<sup>34,45</sup> but in Brazil fatty or  
17 salty foods are considered to give immense pleasure in later life and so difficult for older  
18 patients to forego<sup>40</sup>.

19  
20 Where there were positive relationships between health workers, adherence was facilitated.  
21 Having a good patient –provider relationship increased the likelihood of adherence four times  
22<sup>26</sup>. In Nigeria, the approachability and social reputation of the doctor was linked to greater  
23 adherence<sup>34</sup>. In Indonesia, community health workers encouraged continuity of care in a  
24 community by means of interactive discussions with older patients<sup>25</sup> while in Kenya, good  
25 relationships were identified as increasing retention<sup>30</sup>. However, a traditional hierarchical  
26 relationship between health workers and patients in some countries could act as a barrier, as in  
27 Brazil, where doctors adopted an authoritarian approach to older patients, who often lacked  
28 trust in those providing care<sup>40</sup>.

### 29 30 **Barriers and Facilitators Not Specific To A Single Domain**

31 Two papers trace the patient’s journey overall<sup>31,39</sup>. Most drivers were as in the other papers,  
32 with older women more likely to seek care and limited financial resources impeding continuity  
33 of care, while that those with co-morbidities were more likely to attend appointments. Health  
34 systems related barriers included high costs, medicine stock-outs, inaccessible facilities, and

1 staff absences leading to low levels of satisfaction among patients <sup>31</sup>. Care provided by nurses  
2 was considered to be a potential barrier in Kenya, depending on whether patients accepted them  
3 as primary care givers, or preferred alternative treatments reflecting beliefs in witchcraft <sup>31</sup>.

## 4 5 **Discussion**

6  
7 Control of hypertension remains poor everywhere but especially in LMICs <sup>2</sup>. This systematic  
8 review examines barriers and facilitators along pathways followed by hypertensive patients —  
9 from first symptoms and entry into the system to treatment initiation and follow-up — that lead  
10 to poor control of their condition. We argue that a better understanding of these issues is an  
11 important step in achieving hypertension control, informing design of interventions. Thirty  
12 papers met the inclusion criteria. A conceptual framework with six domains was used to  
13 analyse the findings. The key findings are summarised in Box 1.

### 14 15 *Box 1 Key findings*

- Patients with hypertension confront different barriers and facilitators on their journey through the health system, from diagnosis to treatment initiation to maintenance;
- The effects of barriers accumulate along the patient pathway and characteristics of the health system can reinforce or mitigate them;
- Knowledge and beliefs about hypertension are important at entry in the system but social relationships, traditions and presence of comorbidities become more important later;
- Patient pathways are non-linear and are best characterised as continual cycles of entry and re-entry into the system, as patients seek to accommodate their priorities with respect to health and life in general;
- More evidence is needed on the ways in which individual-, community- and health system-related barriers and facilitators interact, taking account of the patient's perspective and their agency at each stage of the pathway if we are to design nuanced responses that improve hypertension control.

16

1 Several limitations must be acknowledged. The first relates to how access was conceptualised  
2 and what study designs were included. Most studies often reported two points of the care  
3 continuum, typically entry into the system and subsequent retention, and were not designed to  
4 capture intervening barriers and facilitators. Second, even those studies following the patient  
5 along the entire pathway often failed to differentiate the various stages. Third, studies often  
6 take a top-down perspective, defining treatment stages according to a predetermined clinical  
7 pathway or programme intervention, rather than reflecting the perspective of the patients, their  
8 needs and preferences. This was particularly the case for the follow-up stage during which  
9 patients may think their treatment has been completed; thus, the agency of the patients is often  
10 overlooked.

11  
12 Despite these limitations, our findings show that different combinations of barriers appear to  
13 matter at each stage of the care pathway. At entry the key barriers and facilitators relate to how  
14 effectively patients are identified and how they learn about their condition ('health systems  
15 resources and processes' domain) — through primary health care services and/or community-  
16 based screening. The patient's 'knowledge and beliefs about hypertension' domain is also key  
17 at this stage. For example, the asymptomatic nature of hypertension influences how the patient  
18 chooses to manage their condition, as would be expected, given the need for patients to  
19 recognise the importance of seeking care <sup>50</sup>.

20  
21 As patients move along the care pathway, they face an accumulating range of barriers. At the  
22 treatment (medication) initiation stage, most relate to 'health systems resources and processes',  
23 pointing to the importance of a well-functioning health system. Co-morbidities act as a barrier  
24 (with some exceptions) as they complicate treatment. 'Social relations and traditions' also  
25 emerge at this stage and remain important in the follow-up stage.

26  
27 The largest number of studies address the follow-up/ retention stage, which is where a wide  
28 array of issues come into play. Barriers and facilitators spanned all six domains, but the most  
29 important related to poorly resourced and managed health systems, 'patient knowledge and  
30 beliefs' and 'social networks and relationships'. Patients begin to make conscious 'trade-offs'  
31 of continuing treatment against fulfilling family and social roles, starting at the treatment stage  
32 but even more so at follow-up.

33

1 While socio-economic characteristics are often a major issue in studies that examine only one  
2 point of the care pathway, particularly entry, overall they are often mitigated or overcome by  
3 characteristics of the health system and social networks, leading patients to make trade-offs  
4 between continuing treatment and meeting other priorities, such as work and family  
5 commitments.

6  
7 Few studies sought to challenge the linearity of the pathway (from diagnosis to effective  
8 control), with the exception of Gabert et al. who present it as a continuous cycle of entry and  
9 re-entry/ remaining in the system <sup>44</sup>. Most studies see the pathway as normative and singular,  
10 excluding the possibility of diverse trajectories or incomplete cycles constrained by factors  
11 within and beyond the health system. While the qualitative studies often involve an iterative  
12 analysis demonstrating the complexity of the interactions, this is often done only to interpret  
13 the findings and identify policy implications, rather than being integral to study design.

14  
15 Most studies identify independently acting barriers and facilitators of effective care or  
16 hypertension control emerging along the patient pathway, but few explicitly demonstrate how  
17 these distinct factors interact or illustrate in what specific cases or contexts a set of enabling  
18 factors can help to overcome barriers. For example, living close to a health facility could be a  
19 facilitator of treatment, but not if family or social networks discourage access. More  
20 specifically, Atinga et al. argue that factors cannot be viewed as a set of fixed causal sequences,  
21 but rather are interrelated, with each triggering a new cycle of behaviour (causal loops), while  
22 they show that the use of traditional and complementary medicines to treat hypertension could  
23 either result from or lead to perceptions that modern medication is ineffective and inappropriate  
24 <sup>27</sup>.

25  
26 The review demonstrates how social relationships within and outside the health system are  
27 significant independent factors, but also mitigate other factors. Thus, patients observe or  
28 modify their behaviour according to social norms and advice from trusted networks on what is  
29 a serious condition, when to seek modern medicine to treat certain conditions and when to cope  
30 with family/ traditional remedies which often contradict recommended treatment regimens  
31 <sup>46,48,51</sup>. The relationship between providers and patients—reflecting the formal and informal  
32 treatment traditions—appears to be critical. However, information provided to patients is not  
33 always sufficient and understandable (e.g. on how to take their medication, or what are the  
34 consequences of non-adherence to medication <sup>33</sup>).



1  
2 The included studies do not sufficiently capture the patient’s perspective and agency.  
3 Interestingly, while maintaining follow-up is important to clinicians, it may be less so from the  
4 point of view of the patients and their families. They may believe that making contact at the  
5 earlier stages of entry and treatment initiation is more important, while maintaining health  
6 afterwards can be done with their own resources and as time permits given other life  
7 commitments. Furthermore, fundamental beliefs about the nature and progression of disease  
8 and what constitutes a (high quality) treatment are central to care for hypertension, which may  
9 or may not be accepted as a largely asymptomatic condition, as an inherited disease, or as a  
10 part of the natural aging process. These perceptions are nested within a broader set of beliefs  
11 of how to manage life and how to reasonably balance ongoing treatment against other  
12 competing priorities, benefiting not only individuals but their families and social networks.

13  
14 The study has important implications for policy. Stage-specific evidence about barriers to  
15 hypertension care that address the complexity of pathways and interplay of factors, can help to  
16 inform better targeted and effective hypertension control, which is consistent with emerging  
17 conceptions of ‘precision public health’ <sup>52,53</sup>. While measures suggested include tracking  
18 patients, setting-up a reminder system for clinic appointments <sup>33</sup>, there is a recognition that  
19 interventions need to go beyond the health systems, for example to address the multiple  
20 competing demands on patients and their families.

21  
22 There is also a need for health providers to adopt more people-centred treatment approaches  
23 that account for patients' beliefs, values and norms in managing their condition, and to engage  
24 with the knowledge, treatment strategies and experience of medication by patients and their  
25 families <sup>54</sup>, which has also been called as taking a ‘cultural competence therapeutic approach’  
26 <sup>27</sup>. This review is part of a larger project that is consistent with these approaches and sees  
27 patients as active agents, determining how their treatment progresses, and gives them voice  
28 through the opportunities offered by mobile technology <sup>55</sup>. Nevertheless, the balance of  
29 evidence suggests that a more comprehensive mix of measures is required: accessible health  
30 systems resources including information adapted to patients, but also addressing the structural  
31 causes of ill health and the trade-offs made. Health systems interventions and policies need to  
32 engage more closely with these domains, taking the long view.

33

1 Ultimately, the question is whether such an approach matters? This review is part of a lengthy  
2 programme of work we have undertaken over several years in which we have argued for such  
3 a patient-centred approach. This included two of the studies cited, in Malaysia and Colombia  
4 <sup>42,46</sup>. These were used to design complex multi-faceted interventions adapted to each context  
5 and evaluated in a cluster randomised trial that achieved substantially improved control <sup>56</sup>.

6  
7 In conclusion, this review demonstrated that the patient pathway is influenced by a mix of  
8 individual-, community- and health system-related barriers and facilitators that act at different  
9 stages, often interacting. Many of the included studies were designed to capture some but not  
10 all of these, so the ensuing recommendations rarely reflect their complex interplay. More  
11 studies are needed that can distinguish between stages of care, acknowledge both the  
12 formal/normative and informal treatments and actors with which patients engage, and elucidate  
13 the many interacting factors that shape each patient's journey. A more realistic  
14 conceptualisation of the patient pathway is important for more targeted policy  
15 recommendations, and our conceptual framework offers a useful tool to for further research on  
16 hypertension and other chronic conditions.

#### 17 18 **PRISMA Checklist: After References section**

#### 19 20 **References**

- 21 1. GBD 2015 Risk Factors Collaborators. Global, regional, and national comparative risk  
22 assessment of 79 behavioural, environmental and occupational, and metabolic risks or  
23 clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease  
24 Study 2015. *Lancet*. 2016;388(10053):1659-1724. doi:10.1016/s0140-6736(16)31679-  
25 8
- 26 2. Chow CK, Teo KK, Rangarajan S, et al. Prevalence, awareness, treatment, and control  
27 of hypertension in rural and urban communities in high-, middle-, and low-income  
28 countries. *JAMA*. 2013;310(9):959-968. doi:10.1001/jama.2013.184182
- 29 3. Barriers and enabling factors to effective care for hypertension in low and middle  
30 income countries and high income countries: a systematic literature review.  
31 PROSPERO; 2017.  
32 [http://www.crd.york.ac.uk/PROSPERO/display\\_record.php?ID=CRD42017074786](http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42017074786).
- 33 4. WHO. *Everybody's business: Strengthening health systems to improve health*  
34 *outcomes. WHO's framework for action*. Geneva: World Health Organization;2007.

- 1 5. O'Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA. Standards for reporting  
2 qualitative research: a synthesis of recommendations. *Acad Med.* 2014;89(9):1245-  
3 1251. doi:10.1097/ACM.0000000000000388
- 4 6. Schulz KF, Altman DG, Moher D, Group C. CONSORT 2010 statement: updated  
5 guidelines for reporting parallel group randomised trials. *PLoS Med.*  
6 2010;7(3):e1000251. doi:10.1371/journal.pmed.1000251
- 7 7. von Elm E, Altman DG, Egger M, et al. Strengthening the Reporting of Observational  
8 Studies in Epidemiology (STROBE) statement: guidelines for reporting observational  
9 studies. *BMJ.* 2007;335(7624):806-808. doi:10.1136/bmj.39335.541782.AD
- 10 8. Haenssgen MJ, Ariana P. Healthcare access: A sequence-sensitive approach. *SSM*  
11 *Popul Health.* 2017;3:37-47. doi:10.1016/j.ssmph.2016.11.008
- 12 9. Kleinman A. *Patients and Healers in the Context of Culture.* Berkeley: University of  
13 California Press; 1980.
- 14 10. Muela S, Ribera J, Mushi A, Tanner M. Medical syncretism with reference to malaria  
15 in a Tanzanian community. *Social Science & Medicine.* 2002;55:403 - 413.
- 16 11. Baer HA. Medical Pluralism: An Evolving and Contested Concept in Medical  
17 Anthropology. *A companion to medical anthropology.* 2011:405-423.
- 18 12. Scheper-Hughes N. Three propositions for a critically applied medical anthropology.  
19 *Social Science & Medicine.* 1990;30(2):189-197. doi:[https://doi.org/10.1016/0277-](https://doi.org/10.1016/0277-9536(90)90079-8)  
20 [9536\(90\)90079-8](https://doi.org/10.1016/0277-9536(90)90079-8)
- 21 13. Kielmann K, Cataldo F. Engaging with HIV care systems: why space, time and social  
22 relations matter. *Sexually Transmitted Infections.* 2017;93(Suppl 3).  
23 doi:10.1136/sextrans-2017-053173
- 24 14. Brown H. *Living with HIV/AIDS: an ethnography of care in Western Kenya: Social*  
25 *Sciences/Social Anthropology*2010.
- 26 15. Magrath P, Nichter M. Paying for performance and the social relations of health care  
27 provision: An anthropological perspective. *Social Science & Medicine.*  
28 2012;75(10):1778-1785. doi:<https://doi.org/10.1016/j.socscimed.2012.07.025>
- 29 16. Mogensen HO. Finding a path through the health unit: practical experience of Ugandan  
30 patients. *Med Anthropol.* 2005;24(3):209-236. doi:10.1080/01459740500182659
- 31 17. Gilson L, Hanson K, Sheikh K, Agyepong IA, Ssengooba F, Bennett S. Building the  
32 Field of Health Policy and Systems Research: Social Science Matters. *PLOS Medicine.*  
33 2011;8(8):e1001079. doi:10.1371/journal.pmed.1001079

- 1 18. Gilson L. Trust and the development of health care as a social institution. *Social science*  
2 *& medicine*. 2003;56(7):1453-1468.
- 3 19. Wong MC, Jiang JY, Gibbs T, Griffiths SM. Factors associated with antihypertensive  
4 drug discontinuation among Chinese patients: a cohort study. *American Journal of*  
5 *Hypertension*. 2009;22(7):802-810.
- 6 20. Wong MC, Su X, Jiang JY, Tang JL, Griffiths SM. Profiles of discontinuation and  
7 switching of thiazide diuretics: a cohort study among 9398 Chinese hypertensive  
8 patients. *Hypertension Research - Clinical & Experimental*. 2011;34(7):888-893.
- 9 21. Wong MC, Tam WW, Wang HH, et al. Duration of initial antihypertensive prescription  
10 and medication adherence: a cohort study among 203,259 newly diagnosed  
11 hypertensive patients. *International Journal of Cardiology*. 2015;182:503-508.
- 12 22. Zhao P, Wang C, Qin L, et al. Effect of clinical pharmacist's pharmaceutical care  
13 intervention to control hypertensive outpatients in China. *African Journal of Pharmacy*  
14 *and Pharmacology*. 2012;6(1):48-56.
- 15 23. Nguyen QN, Pham ST, Nguyen VL, et al. Implementing a hypertension management  
16 programme in a rural area: local approaches and experiences from Ba-Vi district,  
17 Vietnam. *BMC Public Health*. 2011;11:325.
- 18 24. Ramli A, Ahmad NS, Paraidathathu T. Medication adherence among hypertensive  
19 patients of primary health clinics in Malaysia. *Patient Preference and Adherence*.  
20 2012;6:613-622.
- 21 25. Rahmawati R, Bajorek B. A Community Health Worker-Based Program for Elderly  
22 People With Hypertension in Indonesia: A Qualitative Study, 2013. *Preventing Chronic*  
23 *Disease*. 2015;12:E175.
- 24 26. Mekonnen HS, Gebrie MH, Eyasu KH, Gelagay AA. Drug adherence for  
25 antihypertensive medications and its determinants among adult hypertensive patients  
26 attending in chronic clinics of referral hospitals in Northwest Ethiopia. *BMC*  
27 *Pharmacology & Toxicology*. 2017;18(1):27.
- 28 27. Atinga RA, Yarney L, Gavu NM. Factors influencing long-term medication non-  
29 adherence among diabetes and hypertensive patients in Ghana: A qualitative  
30 investigation. *PLoS ONE [Electronic Resource]*. 2018;13(3):e0193995.
- 31 28. Harries TH, Twumasi-Abosi V, Plange-Rhule J, Cappuccio FP. Hypertension  
32 management in Kumasi: barriers and prejudice? *Journal of Human Hypertension*.  
33 2005;19(12):975-977.

- 1 **29.** Sarfo FS, Mobula LM, Burnham G, et al. Factors associated with uncontrolled blood  
2 pressure among Ghanaians: Evidence from a multicenter hospital-based study. *PLoS*  
3 *ONE [Electronic Resource]*. 2018;13(3):e0193494.
- 4 **30.** Rachlis B, Naanyu V, Wachira J, et al. Identifying common barriers and facilitators to  
5 linkage and retention in chronic disease care in western Kenya. *BMC Public Health*.  
6 2016;16(741).
- 7 **31.** Vedanthan R, Tuikong N, Kofler C, et al. Barriers and facilitators to nurse management  
8 of hypertension: A qualitative analysis from western Kenya. *Ethnicity and Disease*.  
9 2016;26(3):315-322.
- 10 **32.** Subramanian S, Gakunga R, Kibachio J, et al. Cost and affordability of non-  
11 communicable disease screening, diagnosis and treatment in Kenya: Patient payments  
12 in the private and public sectors. *PLoS ONE [Electronic Resource]*.  
13 2018;13(1):e0190113.
- 14 **33.** Nashilongo MM, Singu B, Kalemeera F, et al. Assessing Adherence to  
15 Antihypertensive Therapy in Primary Health Care in Namibia: Findings and  
16 Implications. *Cardiovascular Drugs & Therapy*. 2017;31(5-6):565-578.
- 17 **34.** Odusola AO, Hendriks M, Schultsz C, et al. Perceptions of inhibitors and facilitators  
18 for adhering to hypertension treatment among insured patients in rural Nigeria: a  
19 qualitative study. *BMC Health Services Research*. 2014;14:624.
- 20 **35.** Bovet P, Gervasoni JP, Mkamba M, Balampama M, Lengeler C, Paccaud F. Low  
21 utilization of health care services following screening for hypertension in Dar es Salaam  
22 (Tanzania): a prospective population-based study. *BMC Public Health*. 2008;8:407.
- 23 **36.** Kotwani P, Balzer L, Kwarisiima D, et al. Evaluating linkage to care for hypertension  
24 after community-based screening in rural Uganda. *Tropical Medicine and International*  
25 *Health*. 2014;19(4):459-468.
- 26 **37.** Youssef RM, Moubarak, II. Patterns and determinants of treatment compliance among  
27 hypertensive patients. *Eastern Mediterranean Health Journal*. 2002;8(4-5):579-592.
- 28 **38.** Chung VQ, Morley K, O'Neil E, Ken N, Morley M. Evaluation of a hypertension  
29 screening programme in Independence, Belize. *West Indian Medical Journal*.  
30 2005;54(2):130-134.
- 31 **39.** Ferreira DN, Matos DL, de Loyola Filho AI. Absence of routine medical consultation  
32 among hypertensive and/or diabetic elders: an epidemiological study based on the  
33 Brazilian National Household Survey 2008. *Revista Brasileira de Epidemiologia*.  
34 2015;18(3):578-594.

- 1 **40.** Nations M, Firmo JO, Lima-Costa MF, Uchoa E. Balking blood pressure "control" by  
2 older persons of Bambui, Minas Gerais State, Brazil: an ethno-epidemiological inquiry.  
3 *Cadernos de Saude Publica*. 2011;27 Suppl 3:S378-389.
- 4 **41.** Emmerick ICM, Campos MR, Luiza VL, Chaves LA, Bertoldi AD, Ross-Degnan D.  
5 Retrospective interrupted time series examining hypertension and diabetes medicines  
6 usage following changes in patient cost sharing in the 'Farmacia Popular' programme  
7 in Brazil. *BMJ Open*. 2017;7(11):e017308.
- 8 **42.** Legido-Quigley H, Camacho Lopez PA, Balabanova D, et al. Patients' knowledge,  
9 attitudes, behaviour and health care experiences on the prevention, detection,  
10 management and control of hypertension in Colombia: a qualitative study. *PLoS ONE*  
11 *[Electronic Resource]*. 2015;10(4):e0122112.
- 12 **43.** Duan K, McBain R, Flores H, et al. Implementation and clinical effectiveness of a  
13 community-based non-communicable disease treatment programme in rural Mexico: a  
14 difference-in-differences analysis. *Health Policy & Planning*. 2018;33(6):707-714.
- 15 **44.** Gabert R, Ng M, Sogarwal R, et al. Identifying gaps in the continuum of care for  
16 hypertension and diabetes in two Indian communities. *BMC Health Services Research*.  
17 2017;17(1):846.
- 18 **45.** Nayeri ND, Dehghan M, Iranmanesh S. Being as an iceberg: hypertensive treatment  
19 adherence experiences in southeast of Iran. *Glob Health Action*. 2015;8:28814.
- 20 **46.** Risso-Gill I, Balabanova D, Majid F, et al. Understanding the modifiable health systems  
21 barriers to hypertension management in Malaysia: a multi-method health systems  
22 appraisal approach. *BMC Health Services Research*. 2015;15(254).
- 23 **47.** Shima R, Farizah MH, Majid HA. A qualitative study on hypertensive care behavior in  
24 primary health care settings in Malaysia. *Patient preference and adherence*.  
25 2014;8:1597-1609. doi:10.2147/PPA.S69680
- 26 **48.** Naanyu V, Vedanthan R, Kamano JH, et al. Barriers Influencing Linkage to  
27 Hypertension Care in Kenya: Qualitative Analysis from the LARK Hypertension  
28 Study. *Journal of General Internal Medicine*. 2016;31(3):304-314.
- 29 **49.** Manto A, Dzudie A, Halle MP, et al. Agreement between home and ambulatory blood  
30 pressure measurement in non-dialysed chronic kidney disease patients in Cameroon.  
31 *The Pan African medical journal*. 2018;29:71.
- 32 **50.** MacKian S. *A review of health seeking behaviour: problems and prospects*  
33 *(HSD/WP/05/03)*. Manchester: Health Systems Development Programme, University  
34 of Manchester;2003.

- 1 **51.** Atinga RA, Yarney L, Gavu NM. Factors influencing long-term medication non-  
2 adherence among diabetes and hypertensive patients in Ghana: A qualitative  
3 investigation. *PLoS One*. 2018;13(3):e0193995. doi:10.1371/journal.pone.0193995
- 4 **52.** Dowell SF, Blazes D, Desmond-Hellmann S. Four steps to precision public health.  
5 *Nature News*. 2016;540(7632):189.
- 6 **53.** Olstad DL, McIntyre L. Reconceptualising precision public health. *BMJ Open*.  
7 2019;9(9):e030279. doi:10.1136/bmjopen-2019-030279
- 8 **54.** Department for Health Systems Governance and Service Delivery. *People-centred care*  
9 *in low- and middle-income countries*. Geneva: World Health Organization;2010.
- 10 **55.** Palafox B, Seguin ML, McKee M, et al. Responsive and Equitable Health Systems-  
11 Partnership on Non-Communicable Diseases (RESPOND) study: a mixed-methods,  
12 longitudinal, observational study on treatment seeking for hypertension in Malaysia and  
13 the Philippines. *BMJ Open*. 2018;8(7):e024000. doi:10.1136/bmjopen-2018-024000
- 14 **56.** Schwalm JD, McCready T, Lopez-Jaramillo P, et al. A community-based  
15 comprehensive intervention to reduce cardiovascular risk in hypertension (HOPE 4): a  
16 cluster-randomised controlled trial. *Lancet*. 2019;394(10205):1231-1242.  
17 doi:10.1016/s0140-6736(19)31949-x
- 18

1 PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
<b>TITLE</b>			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
<b>ABSTRACT</b>			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	1
<b>INTRODUCTION</b>			
Rationale	3	Describe the rationale for the review in the context of what is already known.	2
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	3
<b>METHODS</b>			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	3
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	3-5



Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	5
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	5-6
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	5-7
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	5-7
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	5-6
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	6-7
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., $I^2$ ) for each meta-analysis.	6-7

1  
2  
3